Verastem to Present at 2013 Forbes Global CEO Conference


Verastem to Present at 2013 Forbes Global CEO Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc., (NAS: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that Christoph Westphal, M.D., Ph.D., Verastem Executive Chairman, will present this summer at the 2013 Forbes Global CEO Conference ( Now in its 13th year, the Forbes Global CEO Conference will be held from September 3 - 5, 2013.

Will Adamopoulos, Chief Executive Officer of Forbes Media Asia said: "The annual Forbes Global CEO Conference is attended by 400 global CEOs, tycoons, entrepreneurs, up-and-comers, global investors, and thought leaders. Dr. Westphal epitomizes the role of the disruptive entrepreneur in founding, as CEO, several successful public companies, such as Momenta, Alnylam, Sirtris, and now Verastem. We are pleased to include, with Verastem, a global biopharma leader of the future in this important international gathering."

"It is an honor to be invited to speak at the annual Forbes Global CEO conference," said Christoph Westphal, M.D., Ph.D, Verastem Executive Chairman. "At Verastem, we are focused on potential breakthrough therapies targeting cancer stem cells, a driver of many of today's incurable cancers. We have already seen initial clinical activity of our lead compound targeting cancer stem cells in patients with ovarian cancer. This forum provides an important outlet for sharing the ideas that are currently shaping the world of cancer and healthcare research."

"In addition to the encouraging results of our combination trial of lead compound VS-6063 and paclitaxel in ovarian cancer, Verastem will soon initiate a potentially pivotal, multinational, double-blind, placebo controlled study of VS-6063 to treat mesothelioma, a devastating cancer with growing incidence worldwide," added Robert Forrester, Verastem President and Chief Executive Officer. "We are currently evaluating two drug candidates in the clinic and given our potential to address currently incurable cancers in a new way, we are pleased to reach a global audience via the Forbes Global CEO Conference."

About Verastem, Inc.

Verastem, Inc. (NAS: VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit

Forward-looking statements:

This press release includes forward-looking statements about the Company's strategy, future plans and prospects, including statements regarding the development of the Company's compounds, including VS-6063, VS-4718 and VS-5584, and the Company's FAK, PI3K/mTOR and diagnostic programs generally, the timeline for clinical development and regulatory approval of the Company's compounds, the structure of the Company's planned clinical trials and estimates of the Company's ability to fund operations. The words "anticipate," "appear," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks that the preclinical testing of the Company's compounds and preliminary data from clinical trials may not be predictive of the results or success of later clinical trials, that the Company will be unable to successfully complete the clinical development of its compounds, including VS-6063, VS-4718 and VS-5584, that the development of the Company's compounds will take longer or cost more than planned, and that the Company's compounds will not receive regulatory approval or become commercially successful products. Other risks and uncertainties include those identified under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and in any subsequent SEC filings. The forward-looking statements contained in this presentation reflect the Company's current views with respect to future events, and the Company does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Verastem, Inc.
Brian Sullivan, 617-252-9314

KEYWORDS: United States North America Massachusetts


The article Verastem to Present at 2013 Forbes Global CEO Conference originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.